索托维单抗疗法在免疫功能低下患者的血清中引发针对奥密克戎BQ.1.1和XBB.1.5的抗病毒活性。
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.
作者信息
Bruel Timothée, Vrignaud Lou-Léna, Porrot Françoise, Staropoli Isabelle, Planas Delphine, Guivel-Benhassine Florence, Puech Julien, Prot Matthieu, Munier Sandie, Bolland William Henry, Soulié Cathia, Zafilaza Karen, Lusivika-Nzinga Clovis, Meledge Marie-Laure, Dorival Céline, Molino Diana, Péré Hélène, Yordanov Youri, Simon-Lorière Etienne, Veyer David, Carrat Fabrice, Schwartz Olivier, Marcelin Anne-Geneviève, Martin-Blondel Guillaume
机构信息
Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; Antiviral Activities of Antibodies Group, Université Paris Cité, CNRS UMR3569, Paris, France; Vaccine Research Institute, Créteil, France.
Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; Antiviral Activities of Antibodies Group, Université Paris Cité, CNRS UMR3569, Paris, France; Sorbonne Université, Paris, France.
出版信息
Med. 2023 Oct 13;4(10):664-667. doi: 10.1016/j.medj.2023.07.007.
Abstract
Antibodies effective against the recent Omicron sublineages are missing. By taking advantage of a multi-centric prospective cohort of immunocompromised individuals treated for mild-to-moderate COVID-19, Bruel et al. show that administration of 500 mg of sotrovimab induces serum neutralization and antibody-dependent cellular cytotoxicity of BQ.1.1 and XBB.1.5. Therefore, sotrovimab may remain a therapeutic option against these variants.
摘要
目前缺乏对最新奥密克戎亚谱系有效的抗体。通过利用一个多中心前瞻性队列中接受轻度至中度新冠肺炎治疗的免疫功能低下个体，Bruel等人表明，给予500毫克索托维单抗可诱导对BQ.1.1和XBB.1.5的血清中和及抗体依赖性细胞毒性。因此，索托维单抗可能仍然是针对这些变体的一种治疗选择。
相似文献
1
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.索托维单抗疗法在免疫功能低下患者的血清中引发针对奥密克戎BQ.1.1和XBB.1.5的抗病毒活性。
Med. 2023 Oct 13;4(10):664-667. doi: 10.1016/j.medj.2023.07.007.
2
Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients.索托维单抗在接受治疗患者血清中对BQ.1.1和XBB.1.5的抗病毒活性。
medRxiv. 2023 May 30:2023.05.25.23290512. doi: 10.1101/2023.05.25.23290512.
3
Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.在仓鼠模型中评估索特罗维单抗对 BQ.1.1 和 XBB.1 奥密克戎亚谱系的活性。
Antiviral Res. 2023 Jul;215:105638. doi: 10.1016/j.antiviral.2023.105638. Epub 2023 May 18.
4
Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera.奥密克戎变异株 FL.1 和 GE.1 对治疗性抗体和 XBB 血清的中和敏感性。
Virology. 2024 Jul;595:110067. doi: 10.1016/j.virol.2024.110067. Epub 2024 Apr 10.
5
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.接受单克隆抗体治疗的患者体内血清对 SARS-CoV-2 奥密克戎 BA.2、BA.4 和 BA.5 的中和作用的纵向分析。
Cell Rep Med. 2022 Dec 20;3(12):100850. doi: 10.1016/j.xcrm.2022.100850. Epub 2022 Nov 17.
6
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.二价 BNT162b2 疫苗接种的医护人员（有或无风险因素）或感染奥密克戎后，对奥密克戎亚谱系（BA.2/BA.5/BQ.1.1/XBB/XBB.1.5）的中和作用。
Sci Rep. 2023 Oct 13;13(1):17404. doi: 10.1038/s41598-023-44484-x.
7
Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients.严重急性呼吸综合征冠状病毒 2 型奥密克戎感染免疫功能低下患者中索托维单抗逃逸变异的快速选择。
Clin Infect Dis. 2023 Feb 8;76(3):408-415. doi: 10.1093/cid/ciac802.
8
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.245例免疫功能低下患者中针对新冠病毒变异株的单克隆抗体疗法的临床和病毒学结果：一项多中心前瞻性队列研究
Clin Infect Dis. 2024 Jun 14;78(6):1514-1521. doi: 10.1093/cid/ciae026.
9
Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study.奥密克戎时代抗病毒药物联合抗刺突单克隆抗体治疗与单药治疗对轻度至中度SARS-CoV2感染的高危免疫功能低下患者的疗效和安全性：一项前瞻性队列研究
Int J Antimicrob Agents. 2024 Mar;63(3):107095. doi: 10.1016/j.ijantimicag.2024.107095. Epub 2024 Jan 18.
10
Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.在英格兰国民保健服务体系（NHS）医院中，推测接受索托维单抗治疗的新冠病毒疾病（COVID-19）患者的特征及治疗结果
BMC Infect Dis. 2024 Apr 22;24(1):428. doi: 10.1186/s12879-024-09311-2.
引用本文的文献
1
BA.1 breakthrough infection elicits distinct antibody and memory B cell responses in vaccinated-only versus hybrid immunity individuals.BA.1突破性感染在仅接种疫苗者与混合免疫个体中引发不同的抗体和记忆B细胞反应。
iScience. 2025 Feb 5;28(4):111962. doi: 10.1016/j.isci.2025.111962. eCollection 2025 Apr 18.
2
Real-World Effectiveness of Sotrovimab in Patients Infected With SARS-CoV-2 Omicron Subvariant BA.2 in Western Sydney, Australia.索托维单抗在澳大利亚悉尼西部感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎亚型BA.2患者中的真实世界有效性
J Med Virol. 2025 Feb;97(2):e70235. doi: 10.1002/jmv.70235.
3
Clinical features of and severity risk factors for COVID-19 in adults during the predominance of SARS-CoV-2 XBB variants in Okinawa, Japan.日本冲绳地区在 SARS-CoV-2 XBB 变异株流行期间成年人 COVID-19 的临床特征和严重程度危险因素。
PLoS One. 2024 Oct 31;19(10):e0309808. doi: 10.1371/journal.pone.0309808. eCollection 2024.
4
Comparison of Dual Monoclonal Antibody Therapies for COVID-19 Evolution: A Multicentric Retrospective Study.COVID-19 进化的双克隆抗体治疗比较：一项多中心回顾性研究。
Viruses. 2024 Sep 29;16(10):1542. doi: 10.3390/v16101542.
5
and Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients.肾移植受者中抗SARS-CoV-2变体单克隆抗体的中和效力
Transpl Int. 2024 Jul 16;37:13272. doi: 10.3389/ti.2024.13272. eCollection 2024.
6
Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2.通过针对原始严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的记忆B细胞抗体组合实现广泛的沙贝病毒中和作用。
iScience. 2024 Jun 22;27(7):110354. doi: 10.1016/j.isci.2024.110354. eCollection 2024 Jul 19.
7
Akaluc bioluminescence offers superior sensitivity to track dynamics of SARS-CoV-2 infection.Akaluc生物发光在追踪新冠病毒感染动态方面具有更高的灵敏度。
iScience. 2024 Mar 29;27(5):109647. doi: 10.1016/j.isci.2024.109647. eCollection 2024 May 17.
8
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.奥密克戎 XBB 和 BA.2.86/JN.1 分支的 SARS-CoV-2 具有不同的进化特征，表现为适应性增强和抗体逃避能力提高。
Nat Commun. 2024 Mar 13;15(1):2254. doi: 10.1038/s41467-024-46490-7.
9
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎XBB和BA.2.86/JN.1谱系的独特进化，兼具适应性增强和抗体逃避能力。
bioRxiv. 2024 Feb 9:2023.11.20.567873. doi: 10.1101/2023.11.20.567873.
本文引用的文献
1
Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model.在非人灵长类动物模型中，索托维单抗对新冠病毒奥密克戎变种BQ.1.1仍具有活性。
Heliyon. 2023 Jun;9(6):e16664. doi: 10.1016/j.heliyon.2023.e16664. Epub 2023 May 30.
2
Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant.严重急性呼吸综合征冠状病毒2型奥密克戎XBB.1.16变体的病毒学特征
Lancet Infect Dis. 2023 Jun;23(6):655-656. doi: 10.1016/S1473-3099(23)00278-5. Epub 2023 May 3.
3
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.索托维单抗恢复了血液癌症患者对当前奥密克戎亚变种的中和作用。
Cancer Cell. 2023 May 8;41(5):821-823. doi: 10.1016/j.ccell.2023.04.005. Epub 2023 Apr 13.
4
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers.抗体介导的对有症状 COVID-19 的保护作用可以在低血清中和滴度下实现。
Sci Transl Med. 2023 Mar 22;15(688):eadg2783. doi: 10.1126/scitranslmed.adg2783.
5
Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.抗病毒药物对奥密克戎亚型BQ.1.1和XBB的疗效
N Engl J Med. 2023 Jan 5;388(1):89-91. doi: 10.1056/NEJMc2214302. Epub 2022 Dec 7.
6
Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.针对 SARS-CoV-2 奥密克戎变异株关切性的单克隆抗体临床疗效的探索性数据。
Elife. 2022 Nov 22;11:e79639. doi: 10.7554/eLife.79639.
7
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform.在社区患者中比较 sotrovimab 和 molnupiravir 预防重症 COVID-19 结局的效果：利用 OpenSAFELY 平台开展的观察性队列研究。
BMJ. 2022 Nov 16;379:e071932. doi: 10.1136/bmj-2022-071932.
8
WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed.世界卫生组织关于单克隆抗体的治疗方法及COVID-19实用指南需要重新评估。
Lancet. 2022 Dec 17;400(10369):2193-2196. doi: 10.1016/S0140-6736(22)01938-9. Epub 2022 Oct 6.
9
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.S309 和 AZD7442 单克隆抗体治疗对 SARS-CoV-2 奥密克戎谱系株感染的抵抗力。
Nat Commun. 2022 Jul 2;13(1):3824. doi: 10.1038/s41467-022-31615-7.
10
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.无症状和有症状的 SARS-CoV-2 感染会引起多功能抗体。
Cell Rep Med. 2021 May 18;2(5):100275. doi: 10.1016/j.xcrm.2021.100275. Epub 2021 Apr 20.
Zotero 插件